公开(公告)号：US20200339639A1

公开(公告)日：2020-10-29

申请号：US16961345

申请日：2019-01-10

Applicant: UTI Limited Partnership

Inventor： Raymond W. TURNER

IPC: C07K14/435 ,  C07K14/005 ,  A61P43/00 ,  A61K31/65 ,  A61K31/155 ,  A61K31/351

Abstract: The present disclosure relates generally to the treatment of Fragile X Syndrome using a recombinant fusion polypeptide comprising or consisting of a cell penetrating polypeptide, such as HIS or tat, and a Fragile X Mental Retardation protein (FMRP (298)).

公开(公告)号：US20230242599A1

公开(公告)日：2023-08-03

申请号：US18167010

申请日：2023-02-09

Applicant: UTI Limited Partnership

Inventor： Raymond W. TURNER

IPC: C07K14/435 ,  A61P43/00 ,  A61K31/155 ,  A61K31/351 ,  A61K31/65 ,  C07K14/005

CPC classification number: C07K14/435 ,  A61P43/00 ,  A61K31/155 ,  A61K31/351 ,  A61K31/65 ,  C07K14/005 ,  A61K38/00

Abstract: The present disclosure relates generally to the treatment of Fragile X Syndrome using a recombinant fusion polypeptide comprising or consisting of a cell penetrating polypeptide, such as HIS or tat, and a Fragile X Mental Retardation protein (FMRP (298)).

公开(公告)号：US20250026798A1

公开(公告)日：2025-01-23

申请号：US18906893

申请日：2024-10-04

Applicant: UTI Limited Partnership

Inventor： Raymond W. TURNER

IPC: C07K14/435 ,  A61K31/155 ,  A61K31/351 ,  A61K31/65 ,  A61K38/00 ,  A61P43/00 ,  C07K14/005

Abstract: The present disclosure relates generally to the treatment of Fragile X Syndrome using a recombinant fusion polypeptide comprising or consisting of a cell penetrating polypeptide, such as HIS or tat, and a Fragile X Mental Retardation protein (FMRP (298)).